← Russell 3000 cross-section

MRNA Moderna, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$56.8bn
Revenue TTM
$2.2bn
Net income TTM
$-3.2bn
Free cash flow
$-1.2bn
Composite score
35.2
Sector rank
#215

Valuation

P / E
EV / EBITDA
EV / sales
23.5
FCF yield
-2.19%
Earnings yield vs 10-yr
-10.28pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-141.4%
EBITDA margin
-138.7%
ROE
-46.6%
ROIC
-149.9%
Revenue growth
-27.6%

Insider activity, last 90 days

Net open-market
$-35.23m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Total Revenue and Net Loss Per Share For the second quarter of 2026, we recognized total revenue of $145 million, compared to $142 million for the second quarter of 2025. For the three months ended June 30, 2026, total revenue increased by $3 million, or 2%, compared to the same period in 2025. Net product sales decreased by $20 million, or 18%, primarily due to lower COVID vaccine sales in the United States and South America, partially offset by product deliveries in the United Kingdom. …Moderna, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-31

Read the full passage →